

**Study Number:** I16011HR  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**  
**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023  
**Time Report Requested:** 13:24:03  
**Lab:** Burleson Research Technologies

**Study Number:** I16011HR  
**Study Gender:** Female  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.4.3

**Study Number:** I16011HR  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**  
**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine  
**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023  
**Time Report Requested:** 13:24:03  
**Lab:** Burleson Research Technologies

---

**Female: Terminal Day 7**

---

Phase	Observation	Treatment Groups (mg/kg)						
		0	62.5	125	250	500	0.6/0.2 mg/kg DEX	Naive
SD	No Abnormalities Found	10 / 10	10 / 10	10 / 10	10 / 10	10 / 10	10 / 10	5 / 5

---

**Study Number:** I16011HR

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023

**Time Report Requested:** 13:24:03

**Lab:** Burleson Research Technologies

**Female: Terminal Day 8**

Phase	Observation	Treatment Groups (mg/kg)					
		0	62.5	125	250	500	0.6/0.2 mg/kg DEX
SD	Scab Tail	0 / 10	1 / 10 SD 7	0 / 10	0 / 10	1 / 10 SD 7	0 / 10
SD	Wound Tail	0 / 10	1 / 10 SD 6	0 / 10	0 / 10	0 / 10	0 / 10

**Study Number:** I16011HR

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023

**Time Report Requested:** 13:24:03

**Lab:** Burleson Research Technologies

---

**Female: Terminal Day 10**

---

Phase	Observation	Treatment Groups (mg/kg)					
		0	62.5	125	250	500	0.6/0.2 mg/kg DEX
SD	No Abnormalities Found	10 / 10	10 / 10	10 / 10	10 / 10	10 / 10	10 / 10

---

**Study Number:** I16011HR

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023

**Time Report Requested:** 13:24:03

**Lab:** Burleson Research Technologies

**Female: Terminal Day 14**

Phase	Observation	Treatment Groups (mg/kg)					
		0	62.5	125	250	500	0.6/0.2 mg/kg DEX
SD	Alopecia Head; Left	1 / 10 SD 7	0 / 10	0 / 10	0 / 10	0 / 10	0 / 10
SD	Discharge Eye; Left, Red	1 / 10 SD 0	0 / 10	0 / 10	0 / 10	0 / 10	0 / 10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I05: Clinical Observations Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 01/12/2023

Time Report Requested: 13:24:03

Lab: Burleson Research Technologies

Female: Terminal Day 28

Phase	Observation	Treatment Groups (mg/kg)					
		0	62.5	125	250	500	0.6/0.2 mg/kg DEX
SD	Breathing, wheezing	0 / 10	0 / 10	0 / 10	1 / 10 SD 14	0 / 10	0 / 10
SD	Scab Face; Bilateral	0 / 10	0 / 10	0 / 10	0 / 10	0 / 10	1 / 10 SD 24
SD	Scab Face; Right	0 / 10	0 / 10	0 / 10	0 / 10	1 / 10 SD 19	0 / 10
SD	Scab Tail; Right	0 / 10	1 / 10 SD 7	0 / 10	1 / 10 SD 14	0 / 10	0 / 10
SD	Scab Tail	0 / 10	0 / 10	1 / 10 SD 7	0 / 10	0 / 10	0 / 10
SD	Wound Tail	0 / 10	0 / 10	1 / 10 SD 6	0 / 10	0 / 10	0 / 10

**Study Number:** I16011HR

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**I05: Clinical Observations Summary**

**Test Compound:** 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

**CAS Number:** 95737-68-1

**Date Report Requested:** 01/12/2023

**Time Report Requested:** 13:24:03

**Lab:** Burleson Research Technologies

LEGEND

---

Animals exhibiting clinical observations "within normal limits" were recorded as scheduled but are omitted from the table for clarity.

Upper row displays cumulative number of animals with observation / total animals started on study for SD days, total number of pregnant animals for GD days, or total number of littered females for LD days.

Lower row displays day of observation onset

SD – Study Day

DEX = Dexamethazone (0.6 mg/kg study days 3-8 and 0.2 mg/kg study days 9-27)

Naive animals were included to show that work practices did not inadvertently infect the animals.

**\*\* END OF REPORT \*\***